CL2018002495A1 - Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227) - Google Patents

Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)

Info

Publication number
CL2018002495A1
CL2018002495A1 CL2018002495A CL2018002495A CL2018002495A1 CL 2018002495 A1 CL2018002495 A1 CL 2018002495A1 CL 2018002495 A CL2018002495 A CL 2018002495A CL 2018002495 A CL2018002495 A CL 2018002495A CL 2018002495 A1 CL2018002495 A1 CL 2018002495A1
Authority
CL
Chile
Prior art keywords
peptides
cells
expression vectors
nucleic acids
divisional application
Prior art date
Application number
CL2018002495A
Other languages
English (en)
Inventor
Toni Weinschenk
Steffen Walter
Jens Fritsche
Colette Song
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en
Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2018002495A1 publication Critical patent/CL2018002495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Abstract

LA INVENCIÓN SE REFIERE A PÉPTIDOS, ÁCIDOS NUCLÉICOS Y CÉLULAS PARA LA UTILIZACIÓN EN MÉTODOS INMUNOTERAPÉUTICOS. EL DOCUMENTO EN ESTUDIO SE REFIERE A PÉPTIDOS, ÁCIDOS NUCLÉICOS, VECTORES DE EXPRESIÓN, CÉLULAS HOSPEDADORAS, COMPOSICIONES FARMACÉUTICAS, UN MÉTODO PARA PRODUCIR DICHOS PÉPTIDOS, UN MÉTODO PARA PRODUCIR LINFOCITOS ACTIVADOS, LINFOCITOS T ACTIVADOS, UN MÉTODO PERI PRODUCIR UN TCR O STCR, UN AGENTE DE UNIÓN AISLADO, UN RECEPTOR DE LINFOCITO T ACTIVADO, Y SUS USOS PARA EL TRATAMIENTO CONTRA EL CÁNCER.
CL2018002495A 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227) CL2018002495A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862213P 2013-08-05 2013-08-05
GBGB1313987.8A GB201313987D0 (en) 2013-08-05 2013-08-05 Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en) 2014-02-25 2014-02-25 Novel immunotherapy against several tumors, such as lung cancer, including NSCLC

Publications (1)

Publication Number Publication Date
CL2018002495A1 true CL2018002495A1 (es) 2018-10-26

Family

ID=60955422

Family Applications (6)

Application Number Title Priority Date Filing Date
CL2018002279A CL2018002279A1 (es) 2013-08-05 2018-08-10 Péptidos, ácidos nucleicos y células para la utilización en inmunoterapia contra el cáncer (solicitud divisional 201600227)
CL2018002458A CL2018002458A1 (es) 2013-08-05 2018-08-28 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2018002493A CL2018002493A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2018002495A CL2018002495A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2018002494A CL2018002494A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización de inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2021001794A CL2021001794A1 (es) 2013-08-05 2021-07-06 Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227)

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CL2018002279A CL2018002279A1 (es) 2013-08-05 2018-08-10 Péptidos, ácidos nucleicos y células para la utilización en inmunoterapia contra el cáncer (solicitud divisional 201600227)
CL2018002458A CL2018002458A1 (es) 2013-08-05 2018-08-28 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2018002493A CL2018002493A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2018002494A CL2018002494A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización de inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2021001794A CL2021001794A1 (es) 2013-08-05 2021-07-06 Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227)

Country Status (19)

Country Link
US (17) US20170320913A1 (es)
JP (4) JP6646017B2 (es)
KR (2) KR20220045085A (es)
CN (3) CN110041402B (es)
AU (1) AU2022201167A1 (es)
CL (6) CL2018002279A1 (es)
CY (2) CY1122453T1 (es)
ES (1) ES2900004T3 (es)
HR (2) HRP20211852T1 (es)
HU (1) HUE057334T2 (es)
IL (5) IL300761A (es)
LT (1) LT3456339T (es)
MX (3) MX2021001914A (es)
MY (1) MY191939A (es)
PH (3) PH12018501901A1 (es)
PL (1) PL3456339T3 (es)
PT (1) PT3456339T (es)
RS (1) RS62602B1 (es)
SI (1) SI3456339T1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
RS62602B1 (sr) 2013-08-05 2021-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
CN112521484A (zh) * 2020-12-03 2021-03-19 佛山市第一人民医院（中山大学附属佛山医院） 结肠癌肿瘤特异tcr序列及其应用
CN112691195B (zh) * 2021-02-02 2023-03-14 黑龙江省科学院高技术研究院 Prpf8表达抑制剂在制备治疗肺癌的药物中的应用
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
AU2205499A (en) 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human regulatory proteins
US7094890B1 (en) 2000-03-10 2006-08-22 Novartis Ag Arthritis-associated protein
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP2005500059A (ja) 2001-08-13 2005-01-06 ダナ−ファーバー キャンサー インスティテュート インク． ペリオスチンに基づく診断アッセイ法
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
AU2003262789A1 (en) * 2002-08-20 2004-03-11 Aventis Pharma Sa Abca13 nucleic acids and proteins, and uses thereof
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
ATE511550T1 (de) * 2003-07-17 2011-06-15 Pacific Edge Biotechnology Ltd Marker zum nachweis von magenkrebs
EP1714157A2 (en) 2004-01-28 2006-10-25 Immatics Biotechnologies GmbH Method for identifying and quantifying of tumour-associated peptides
US20060019284A1 (en) 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
SI1760088T1 (sl) 2005-09-05 2008-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II
EA200801865A1 (ru) 2006-02-22 2009-02-27 Филоджен Спа Опухолевые маркеры сосудов
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
PL2338907T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
WO2009036246A2 (en) 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
US8134459B2 (en) 2007-10-19 2012-03-13 Smiths Medical Asd, Inc. Wireless telecommunications system adaptable for patient monitoring
US20100310640A1 (en) 2007-11-01 2010-12-09 Knutson Keith L Hla-dr binding peptides and their uses
EP2250287B1 (en) 2008-02-19 2013-09-18 MDxHealth SA Detection and prognosis of lung cancer
AU2009221915A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
CA2720563A1 (en) 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2010037124A1 (en) * 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2010045388A2 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
GB2477705B (en) 2008-11-17 2014-04-23 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
CN101824400B (zh) * 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
US20110033516A1 (en) 2009-08-06 2011-02-10 Medical University Of South Carolina Methods and compositions for bone healing by periostin
US8281223B2 (en) 2009-08-07 2012-10-02 Via Technologies, Inc. Detection of fuse re-growth in a microprocessor
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9028810B2 (en) 2010-12-20 2015-05-12 Ajou University Industry—Academic Cooperations Foundatin Composition for inducing migration of neural stem cells containing periostin as effective ingredient
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
RS62602B1 (sr) * 2013-08-05 2021-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202111399YA (en) * 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Also Published As

Publication number Publication date
CL2021001794A1 (es) 2022-02-25
US10323065B1 (en) 2019-06-18
SI3456339T1 (sl) 2022-01-31
MX2021001914A (es) 2021-04-28
PH12020500433A1 (en) 2021-01-11
IL295031B2 (en) 2023-08-01
US20220064220A1 (en) 2022-03-03
US11939400B2 (en) 2024-03-26
US20200031870A1 (en) 2020-01-30
US20210253640A1 (en) 2021-08-19
US11866517B2 (en) 2024-01-09
PT3456339T (pt) 2021-12-09
US11814446B2 (en) 2023-11-14
US20190322703A1 (en) 2019-10-24
US10160786B1 (en) 2018-12-25
AU2022201167A1 (en) 2022-03-17
US20190177369A1 (en) 2019-06-13
US11859017B2 (en) 2024-01-02
CN110041402B (zh) 2024-04-16
JP2018038388A (ja) 2018-03-15
US20200031869A1 (en) 2020-01-30
IL295031B1 (en) 2023-04-01
US20200031868A1 (en) 2020-01-30
CY1124950T1 (el) 2023-01-05
JP2020010686A (ja) 2020-01-23
CN110041403B (zh) 2023-03-10
MY191939A (en) 2022-07-19
PL3456339T3 (pl) 2022-03-21
LT3456339T (lt) 2021-12-10
US10479818B2 (en) 2019-11-19
JP2022130482A (ja) 2022-09-06
US20220298207A1 (en) 2022-09-22
US20190002504A1 (en) 2019-01-03
US10316062B1 (en) 2019-06-11
US11939401B2 (en) 2024-03-26
JP7039044B2 (ja) 2022-03-22
ES2900004T3 (es) 2022-03-15
MX2018010565A (es) 2021-11-16
US20200017551A1 (en) 2020-01-16
US11161879B2 (en) 2021-11-02
HRP20211852T1 (hr) 2022-03-18
US10316063B1 (en) 2019-06-11
IL300761A (en) 2023-04-01
JP7094572B2 (ja) 2022-07-04
CN109748953B (zh) 2022-09-02
IL280565B (en) 2022-09-01
US20190169233A1 (en) 2019-06-06
JP6646017B2 (ja) 2020-02-14
KR102383710B1 (ko) 2022-04-08
KR20200037457A (ko) 2020-04-08
MX2019011621A (es) 2019-12-05
JP2020072717A (ja) 2020-05-14
US10487116B2 (en) 2019-11-26
CN110041403A (zh) 2019-07-23
CY1122453T1 (el) 2021-01-27
PH12021551208A1 (en) 2022-02-14
IL269753B (en) 2021-03-25
CN110041402A (zh) 2019-07-23
US10793602B2 (en) 2020-10-06
KR20220045085A (ko) 2022-04-12
US20200031867A1 (en) 2020-01-30
RS62602B1 (sr) 2021-12-31
PH12018501901A1 (en) 2019-04-15
IL262509B (en) 2022-02-01
CL2018002494A1 (es) 2018-10-26
US11161880B2 (en) 2021-11-02
IL262509A (en) 2018-12-31
US20190177368A1 (en) 2019-06-13
CL2018002458A1 (es) 2018-10-12
US20190218254A1 (en) 2019-07-18
IL269753A (en) 2019-11-28
US11161877B2 (en) 2021-11-02
CL2018002493A1 (es) 2018-11-09
CN109748953A (zh) 2019-05-14
US20220281917A1 (en) 2022-09-08
US20220194984A1 (en) 2022-06-23
US11161878B2 (en) 2021-11-02
HUE057334T2 (hu) 2022-05-28
US20170320913A1 (en) 2017-11-09
IL280565A (en) 2021-03-25
IL295031A (en) 2022-09-01
CL2018002279A1 (es) 2018-09-14
HRP20192262T1 (hr) 2020-03-06

Similar Documents

Publication Publication Date Title
CL2018002493A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2021001545A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
BR112017004675A2 (pt) receptores quiméricos e usos dos mesmos em terapia imunológica
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CO2019006914A2 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
CR20160531A (es) Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
BR112018071466A2 (pt) novos peptídeos de ligação a cd1d imunogênicos
BR112017016681A2 (pt) vetor de coexpressão de vacina e moléculas coestimulatórias
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
MX2018002665A (es) Combinacion que comprende oligonucleotidos inmunoestimulantes.
BR112016027595A8 (pt) produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
CL2021002168A1 (es) Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407).
MX2015017959A (es) Composiciones y metodos para inmunoterapia.